

Ryotaro Nakamura

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6741421/publications.pdf>

Version: 2024-02-01

185
papers

5,418
citations

94433

37
h-index

95266

68
g-index

187
all docs

187
docs citations

187
times ranked

5779
citing authors

#	ARTICLE	IF	CITATIONS
1	The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. <i>Haematologica</i> , 2023, 108, 150-160.	3.5	10
2	Severe Acute Respiratory Syndrome Coronavirus 2–Specific Monoclonal Antibody for the Treatment of Mild to Moderate Coronavirus Disease 2019 in Cancer Patients: A Single-Center Experience. <i>Journal of Infectious Diseases</i> , 2022, 225, 352-354.	4.0	7
3	Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study. <i>Blood Advances</i> , 2022, 6, 1444-1453.	5.2	13
4	Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia. <i>Cancer</i> , 2022, 128, 529-535.	4.1	17
5	Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 111.e1-111.e8.	1.2	16
6	Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. <i>JAMA Oncology</i> , 2022, 8, 404.	7.1	32
7	Successful outcome of pre-engraftment COVID-19 in an HCT patient: impact of targeted therapies and cellular immunity. <i>Blood Advances</i> , 2022, 6, 1645-1650.	5.2	5
8	Large-scale manufacturing and characterization of CMV-CD19CAR T cells. , 2022, 10, e003461.		9
9	Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 187.e1-187.e10.	1.2	3
10	Pharmacometabonomic association of cyclophosphamide 4- α -hydroxylation in hematopoietic cell transplant recipients. <i>Clinical and Translational Science</i> , 2022, 15, 1215-1224.	3.1	6
11	High prevalence and inferior long-term outcomes for TP53 mutations in therapy-related acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	4
12	Successful treatment of refractory pure red cell aplasia in major ABO-mismatched allogeneic hematopoietic stem cell transplant with single agent lbrutinib. <i>Bone Marrow Transplantation</i> , 2022, 57, 830-833.	2.4	2
13	Total Marrow and Lymphoid Irradiation with Post-Transplantation Cyclophosphamide for Patients with AML in Remission. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 368.e1-368.e7.	1.2	4
14	Long-term follow-up of patients with poor-risk acute leukemia treated on a phase 2 trial undergoing intensified conditioning regimen prior to allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2022, 63, 1220-1226.	1.3	2
15	Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2022, 196, .	2.5	6
16	Clinical and immunologic responses to extracorporeal photopheresis and low-dose IL-2 in patients with steroid refractory chronic graft-versus host disease. <i>Bone Marrow Transplantation</i> , 2022, 57, 1045-1047.	2.4	4
17	Retention of Donor T Cells in Lymphohematopoietic Tissue and Augmentation of Tissue PD-L1 Protection for Prevention of GVHD While Preserving GVL Activity. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	1
18	Association Between Body Composition and Development of Glucose Intolerance after Allogeneic Hematopoietic Cell Transplantation. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 2004-2010.	2.5	3

#	ARTICLE	IF	CITATIONS
19	Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL. <i>Blood Advances</i> , 2022, 6, 4936-4948.	5.2	7
20	Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide. <i>Blood Advances</i> , 2022, 6, 4098-4106.	5.2	9
21	Prediction of Acute Graft versus Host Disease and Relapse by Endogenous Metabolomic Compounds in Patients Receiving Personalized Busulfan-Based Conditioning. <i>Journal of Proteome Research</i> , 2021, 20, 684-694.	3.7	6
22	Tissue-resident PSGL1 ^{lo} CD4 ⁺ T cells promote B cell differentiation and chronic graft-versus-host disease-associated autoimmunity. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	21
23	Explainable Tree-Based Predictions for Unplanned 30-Day Readmission of Patients With Cancer Using Clinical Embeddings. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 155-167.	2.1	9
24	Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors. <i>Blood Advances</i> , 2021, 5, 975-983.	5.2	27
25	Atrial Fibrillation in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2021, 39, 902-910.	1.6	15
26	Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 255.e1-255.e9.	1.2	6
27	Cytokine gene polymorphisms are associated with response to blinatumomab in B-cell acute lymphoblastic leukemia. <i>European Journal of Haematology</i> , 2021, 106, 851-858.	2.2	2
28	Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (<sc>HMA</sc> or liposomal daunorubicin<sc>CPX</sc>+cytarabine (<sc>CPX</sc>+CS51). <i>American Journal of Hematology</i> , 2021, 96, E196-E200.	4.1	10
29	Late-occurring infections in a contemporary cohort of hematopoietic cell transplantation survivors. <i>Cancer Medicine</i> , 2021, 10, 2956-2966.	2.8	6
30	Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). <i>Blood Advances</i> , 2021, 5, 2481-2489.	5.2	25
31	Efficacy of blinatumomab for MRD relapse in ALL post allogenic HCT. <i>Leukemia Research</i> , 2021, 104, 106579.	0.8	4
32	Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2464-2470.	2.4	8
33	Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2021, 39, 3328-3339.	1.6	72
34	Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant. <i>Blood Advances</i> , 2021, 5, 2650-2659.	5.2	29
35	Acute GVHD Diagnosis and Adjudication in a Multicenter Trial: A Report From the BMT CTN 1202 Biorepository Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 1878-1887.	1.6	14
36	Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes. <i>Blood Cancer Journal</i> , 2021, 11, 125.	6.2	2

#	ARTICLE	IF	CITATIONS
37	Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 938.e1-938.e6.	1.2	63
38	Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 921.e1-921.e10.	1.2	11
39	Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 988.e1-988.e7.	1.2	10
40	Incidence and Risk Factors for De Novo Cutaneous Squamous Cell Carcinoma in a Contemporary Cohort of Long-Term Hematopoietic Cell Transplantation Survivors. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2073-2076.e5.	0.7	1
41	Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine. <i>International Journal of Hematology</i> , 2021, 114, 544-553.	1.6	6
42	Current Management and New Developments in the Treatment of Myelodysplastic Syndrome. <i>Cancer Treatment and Research</i> , 2021, 181, 115-132.	0.5	2
43	Outcomes of Venetoclax and Hypomethylating Agents (HMA) in Adult Patients with KMT2A-Rearranged Leukemias. <i>Blood</i> , 2021, 138, 3430-3430.	1.4	2
44	Use of Monoclonal Antibody Therapy in Hematologic Patients with Mild-to-Moderate COVID-19: A Retrospective Single-Center Experience. <i>Blood</i> , 2021, 138, 3037-3037.	1.4	0
45	Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimens. <i>Bone Marrow Transplantation</i> , 2021, , .	2.4	2
46	Superior Outcomes with Fludarabine-Busulfan (Flu/Bu) Based Conditioning for Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis - a Comparative Analysis By CIBMTR. <i>Blood</i> , 2021, 138, 912-912.	1.4	3
47	The Impact of Somatic Mutations on Allogeneic Hematopoietic Cell Transplantation in Chronic Myelomonocytic Leukemia: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. <i>Blood</i> , 2021, 138, 417-417.	1.4	0
48	Prognostic Value of Elafin in Acute Graft-Versus-Host Disease. <i>Blood</i> , 2021, 138, 3900-3900.	1.4	0
49	A Randomized Open Label Pilot Study of <i>Clostridium Butyricum</i> Miyairi 588 (CBM588) in Recipients of Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2021, 138, 334-334.	1.4	1
50	Prediction of Graft-Versus-Host Disease in Recipients of Single Mismatched Unrelated Hematopoietic Cell Transplantation Donor Using a Highly Multiplexed Proteomic Assay, MHC-Pepseq. <i>Blood</i> , 2021, 138, 1808-1808.	1.4	0
51	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Adults with Ph-like ALL. <i>Blood</i> , 2021, 138, 3955-3955.	1.4	0
52	A Phase II Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy of Cmvpepvax for Preventing CMV Reactivation/Disease after Matched Related/Unrelated Donor Hematopoietic Cell Transplant. <i>Blood</i> , 2021, 138, 2887-2887.	1.4	0
53	The Impact of Letermovir (LTV) Prophylaxis on Early Cytomegalovirus Infection (CMVi) and Outcomes in the Adult Allogeneic Hematopoietic Cell Transplantation (alloHCT) Recipients with High-Risk Donor Type. <i>Blood</i> , 2021, 138, 1776-1776.	1.4	0
54	Social Vulnerability Is a Clinically Important Predictor of Outcomes after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2021, 138, 842-842.	1.4	1

#	ARTICLE	IF	CITATIONS
55	Favorable outcomes for allogeneic hematopoietic cell transplantation in elderly patients with NPM1-mutated and FLT3-ITD-negative acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2020, 55, 473-475.	2.4	11
56	Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 292-299.	2.0	13
57	Protective effect of HLA-DPB1 mismatch remains valid in reduced-intensity conditioning unrelated donor hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 409-418.	2.4	6
58	Efficacy of low-dose zoster prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1662-1664.	2.4	5
59	Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis. <i>Bone Marrow Transplantation</i> , 2020, 55, 877-883.	2.4	13
60	Comparison of outcomes of HCT in blast phase of <i>BCR-ABL1</i> MPN with de novo AML and with AML following MDS. <i>Blood Advances</i> , 2020, 4, 4748-4757.	5.2	14
61	Poxvirus Vectored Cytomegalovirus Vaccine to Prevent Cytomegalovirus Viremia in Transplant Recipients. <i>Annals of Internal Medicine</i> , 2020, 172, 306.	3.9	45
62	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020, 4, 3180-3190.	5.2	18
63	Technology-enabled activation of skin cancer screening for hematopoietic cell transplantation survivors and their primary care providers (TEACH). <i>BMC Cancer</i> , 2020, 20, 721.	2.6	1
64	Red blood cell and platelet transfusion support in the first 30 and 100 days after allogeneic hematopoietic cell transplant. <i>Transfusion</i> , 2020, 60, 2225-2242.	1.6	9
65	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2139-2146.	2.0	14
66	Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e322-e327.	2.0	32
67	Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation. <i>Blood Advances</i> , 2020, 4, 2073-2083.	5.2	39
68	Survival following allogeneic transplant in patients with myelofibrosis. <i>Blood Advances</i> , 2020, 4, 1965-1973.	5.2	63
69	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2020, 105, 1329-1338.	3.5	23
70	Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1425-1432.	2.0	5
71	Iron Overload Is Associated with Delayed Engraftment and Increased Nonrelapse Mortality in Recipients of Umbilical Cord Blood Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1697-1703.	2.0	6
72	Long-term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation From Unrelated Donor Using Tacrolimus/Sirolimus-based GvHD Prophylaxis: Impact of HLA Mismatch. <i>Transplantation</i> , 2020, 104, 1070-1080.	1.0	9

#	ARTICLE	IF	CITATIONS
73	Feasibility and Acceptability of Using a Telehealth Platform to Monitor Cardiovascular Risk Factors in Hematopoietic Cell Transplantation Survivors at Risk for Cardiovascular Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1233-1237.	2.0	13
74	Ruxolitinib for the treatment of graft-versus-host disease. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 347-359.	3.0	15
75	The efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia with extramedullary involvement. <i>Leukemia and Lymphoma</i> , 2020, 61, 2020-2023.	1.3	15
76	Abnormal body composition is a predictor of adverse outcomes after autologous haematopoietic cell transplantation. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 962-972.	7.3	19
77	A Phase II Trial of Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S188.	2.0	3
78	Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia. <i>American Journal of Hematology</i> , 2020, 95, 1193-1199.	4.1	28
79	Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e94-e100.	2.0	3
80	Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1084-1090.	2.0	19
81	Cost analysis of ganciclovir and foscarnet in recipients of allogeneic hematopoietic cell transplant with cytomegalovirus viremia. <i>Transplant Infectious Disease</i> , 2020, 22, e13233.	1.7	1
82	Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant. <i>Leukemia</i> , 2020, 34, 1898-1906.	7.2	16
83	Decision Analysis of Transplantation for Patients with Myelodysplasia: "Who Should We Transplant Today?" <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 305-315.	2.3	1
84	Impact of Genetic Mutations on the Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia with Antecedent Myeloproliferative Neoplasm. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S12.	2.0	3
85	Conditional Survival, Cause-Specific Mortality, and Risk Factors of Late Mortality After Allogeneic Hematopoietic Cell Transplantation. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1153-1161.	6.3	20
86	A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102. <i>Blood</i> , 2020, 136, 19-21.	1.4	12
87	Clinical Outcomes of Patients with Secondary Acute Myeloid Leukemia (sAML) Treated with Hypomethylating Agent Plus Venetoclax (HMA-Ven) or Liposomal Daunorubicin Cytarabine (CPX-351). <i>Blood</i> , 2020, 136, 37-38.	1.4	2
88	Efficacy of Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Peripheral Blood Stem Cell HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation; A Prospective Pilot Trial. <i>Blood</i> , 2020, 136, 49-50.	1.4	2
89	Biomarker-guided preemption of steroid-refractory graft-versus-host disease with $\hat{\pm}$ -1-antitrypsin. <i>Blood Advances</i> , 2020, 4, 6098-6105.	5.2	24
90	Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 599-634.	4.9	33

#	ARTICLE	IF	CITATIONS
91	Younger HLA-Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (allo-HCT) for Myelodysplastic Syndromes (MDS) Is Associated with Superior Disease-Free Survival Compared to Older HLA-Identical Sibling Donors: CIBMTR Analysis. <i>Blood</i> , 2020, 136, 43-44.	1.4	1
92	Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in T-Cell Prolymphocytic Leukemia (T-PLL): An Analysis from the CIBMTR. <i>Blood</i> , 2020, 136, 28-29.	1.4	0
93	Alternative Donor Hematopoietic Cell Transplantation for Pediatric, Adolescent and Young Adult with Hematological Diseases. <i>Blood</i> , 2020, 136, 5-6.	1.4	0
94	Vaccination of Hematopoietic Stem Cell (HCT) Donors with Triplex, a Novel Cytomegalovirus Vaccine: Safety, Feasibility and Adoptive Transfer of Protective CMV-Specific T Cells in HCT Recipients. <i>Blood</i> , 2020, 136, 33-33.	1.4	0
95	Hemorrhagic Cystitis in Patients Undergoing Allogeneic Hematopoietic Cell Transplant with Post Transplant Cyclophosphamide As GvHD Prophylaxis. <i>Blood</i> , 2020, 136, 21-22.	1.4	0
96	Clinical Impact of Cytokine Release Syndrome on Outcomes of Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide. <i>Blood</i> , 2020, 136, 10-11.	1.4	0
97	Healthcare Resource Utilization in Transplant Patients Who Are at a Higher-Risk to Develop Cytomegalovirus Infection during Their Primary Transplant-Related Hospitalization. <i>Blood</i> , 2020, 136, 16-17.	1.4	0
98	Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for Autologous Hematopoietic Cell Transplantation (AHCT) in Patients with Mature T-Cell NON-Hodgkin Lymphoma, the "a-TAC-BEAM Regimen". <i>Blood</i> , 2020, 136, 10-11.	1.4	0
99	Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. <i>American Journal of Hematology</i> , 2019, 94, E253-E255.	4.1	62
100	Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2002-2007.	2.0	64
101	Influence of donor KIR genotypes on reduced relapse risk in acute myelogenous leukemia after hematopoietic stem cell transplantation in patients with CMV reactivation. <i>Leukemia Research</i> , 2019, 87, 106230.	0.8	9
102	RBC and platelet transfusion support in the first 30 and 100 days after haploidentical hematopoietic stem cell transplantation. <i>Transfusion</i> , 2019, 59, 3371-3385.	1.6	11
103	Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2019, 187, e45-e48.	2.5	49
104	Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e400-e405.	0.4	12
105	MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen. <i>Blood Advances</i> , 2019, 3, 83-95.	5.2	51
106	Post-Allogeneic Hematopoietic Stem Cell Transplantation Eculizumab as Prophylaxis Against Hemolysis and Thrombosis for Patients with Hematologic Disorders Associated with Paroxysmal Nocturnal Hemoglobinuria Clones. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e183-e185.	2.0	7
107	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019, 3, 1826-1836.	5.2	89
108	Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents. <i>Blood Advances</i> , 2019, 3, 4043-4049.	5.2	55

#	ARTICLE	IF	CITATIONS
109	Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 287-292.	2.0	6
110	Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 265-269.	2.0	62
111	Rapid Acquisition of Cytomegalovirus-Specific T Cells with a Differentiated Phenotype, in Nonviremic Hematopoietic Stem Transplant Recipients Vaccinated with CMVPepVax. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 771-784.	2.0	12
112	Effect of isavuconazole on tacrolimus and sirolimus serum concentrations in allogeneic hematopoietic stem cell transplant patients: A drug-drug interaction study. <i>Transplant Infectious Disease</i> , 2019, 21, e13007.	1.7	19
113	Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Flurabine Improves Transplant Outcomes in Older MDS Patients. <i>Blood</i> , 2019, 134, 253-253.	1.4	1
114	Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administration in Combination with Reduced Intensity Conditioning. <i>Blood</i> , 2019, 134, 669-669.	1.4	4
115	Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplantation: Outcome Data Analysis. <i>Blood</i> , 2019, 134, 4518-4518.	1.4	1
116	Large-Scale Manufacturing of CMV-CD19CAR T Cells and Characterization of Their Biologic and Immunologic Properties. <i>Blood</i> , 2019, 134, 3247-3247.	1.4	1
117	Updated Analysis: Novel Machine-Learning-Based Sepsis Prediction Model for Patients Undergoing Hematopoietic Stem Cell Transplantation (Early Sepsis Prediction/Identification for Transplant) <i>Tj ETQq1 1 0.7843 14rgBT /Overlock 1</i>		
118	The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1322-1340.	2.0	85
119	MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. <i>Blood</i> , 2018, 131, 2846-2855.	1.4	140
120	Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. <i>Haematologica</i> , 2018, 103, e404-e407.	3.5	212
121	A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection. <i>Expert Review of Vaccines</i> , 2018, 17, 889-911.	4.4	42
122	Prediction of cardiovascular disease among hematopoietic cell transplantation survivors. <i>Blood Advances</i> , 2018, 2, 1756-1764.	5.2	53
123	Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1828-1835.	2.0	15
124	Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to <i>de novo</i> acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients. <i>Haematologica</i> , 2018, 103, 1662-1668.	3.5	41
125	Phase I Study of Yttrium-90 Labeled ANTI-CD25 (aTac) Monoclonal Antibody PLUS BEAM for Autologous Hematopoietic CELL Transplantation (AHCT) in Patients with Mature T-CELL NON-Hodgkin Lymphoma, the "a-TAC-BEAM Regimen". <i>Blood</i> , 2018, 132, 611-611.	1.4	7
126	A Machine-Learning Sepsis Prediction Model for Patients Undergoing Hematopoietic Cell Transplantation. <i>Blood</i> , 2018, 132, 711-711.	1.4	5

#	ARTICLE	IF	CITATIONS
127	Incidence and Risk Factors of CMV Reactivation after Haploidentical Hematopoietic Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide - Possible Role of Donor KIR Genotypes. <i>Blood</i> , 2018, 132, 3416-3416.	1.4	1
128	MIPSS70+ V2.0 and Revised Cytogenetics Changes Predict Outcomes of Allogeneic Transplantation with Fludarabine and Melphalan Conditioning in Patients with Myelofibrosis. <i>Blood</i> , 2018, 132, 1752-1752.	1.4	0
129	Serial Biomarker Monitoring Early after HCT Identifies Different Risks for Relapse and Graft-Vs-Host Disease. <i>Blood</i> , 2018, 132, 356-356.	1.4	0
130	Cytokine Gene Polymorphisms Are Associated with Disease Response to Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 1549-1549.	1.4	0
131	Effect of Vancomycin-Resistance Enterococci Colonization Status Prior to Allogeneic Hematopoietic Cell Transplantation on Transplant Outcomes: A Single Center Retrospective Experience. <i>Blood</i> , 2018, 132, 3386-3386.	1.4	0
132	Muscle Depletion Is an Important and Clinically Relevant Predictor of Outcomes after Autologous Hematopoietic Cell Transplantation. <i>Blood</i> , 2018, 132, 620-620.	1.4	0
133	Clinical Outcomes of MDS Patients Who Were Allogeneic Hematopoietic Stem Cell Transplant Candidates but Did Not Proceed with Transplantation. <i>Blood</i> , 2018, 132, 2181-2181.	1.4	0
134	MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults. <i>Blood</i> , 2017, 129, 114-125.	1.4	69
135	Phase I Trial of Total Marrow and Lymphoid Irradiation Transplantation Conditioning in Patients with Relapsed/Refractory Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 618-624.	2.0	84
136	PD-1 blockade for relapsed lymphoma postâ€“allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. <i>Blood</i> , 2017, 130, 221-228.	1.4	214
137	Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia. <i>Haematologica</i> , 2017, 102, 1291-1298.	3.5	38
138	Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of <i>TP53</i> mutational status. <i>Haematologica</i> , 2017, 102, 2030-2038.	3.5	26
139	Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. <i>Blood</i> , 2017, 130, 2243-2250.	1.4	352
140	Philadelphia chromosome as a recurrent event among therapyâ€“related acute leukemia. <i>American Journal of Hematology</i> , 2017, 92, E18-E19.	4.1	11
141	An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. <i>JCI Insight</i> , 2017, 2, e89798.	5.0	166
142	Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cellâ€“Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. <i>Journal of Clinical Oncology</i> , 2017, 35, 3002-3009.	1.6	255
143	Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1348-1356.	2.0	76
144	Dasatinib-Induced Colitis after Allogeneic Stem Cell Transplantation for Philadelphia Chromosomeâ€“Positive Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1900-1903.	2.0	47

#	ARTICLE	IF	CITATIONS
145	Outcome of Second Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 519-522.	0.4	8
146	Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial. <i>Lancet Haematology</i> , 2016, 3, e87-e98.	4.6	67
147	Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 268-276.	2.0	36
148	Incidence and Predictors of Late-Occurring Central Nervous System Complications in Allogeneic Hematopoietic Cell Transplant Survivors. <i>Blood</i> , 2016, 128, 5799-5799.	1.4	0
149	Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. <i>Blood</i> , 2015, 126, 1033-1040.	1.4	565
150	Management of Drug Interaction between Posaconazole and Sirolimus in Patients Who Undergo Hematopoietic Stem Cell Transplant. <i>Pharmacotherapy</i> , 2015, 35, 578-585.	2.6	14
151	CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells. <i>Clinical Cancer Research</i> , 2015, 21, 2993-3002.	7.0	52
152	Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1 dose de-escalation study. <i>Lancet Haematology</i> , 2015, 2, e367-e375.	4.6	64
153	Long-Term Survival after Transplantation of Unrelated Donor Peripheral Blood or Bone Marrow Hematopoietic Cells for Hematologic Malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 55-59.	2.0	34
154	Remission Induction in a Phase I/II Study of an Anti-CD20-Interleukin-2 Immunocytokine DI-Leu16-IL2 in Patients with Relapsed B-Cell Lymphoma. <i>Blood</i> , 2015, 126, 1533-1533.	1.4	14
155	Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation. <i>Haematologica</i> , 2014, 99, 1868-1875.	3.5	19
156	Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: considerations for evidence-based GVHD prophylaxis. <i>Expert Review of Hematology</i> , 2014, 7, 407-421.	2.2	12
157	Ex vivo detection of CD8 T cells specific for H-Y minor histocompatibility antigens in allogeneic hematopoietic stem cell transplant recipients. <i>Transplant Immunology</i> , 2014, 30, 128-135.	1.2	4
158	Multicenter Biologic Assignment Trial Comparing Reduced-Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50 to 75 with Intermediate-2 and High-Risk Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network #1102 Study Rationale, Design, and Methods. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1566-1572.	2.0	24
159	Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis. <i>Journal of Clinical Oncology</i> , 2014, 32, 3264-3274.	1.6	146
160	Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. <i>Blood</i> , 2014, 124, 1372-1377.	1.4	178
161	Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. <i>Blood</i> , 2014, 124, 3221-3227.	1.4	92
162	Detection and preliminary characterization of CD8+ T lymphocytes specific for Wilms' tumor antigen in patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 2490-2499.	1.3	4

#	ARTICLE	IF	CITATIONS
163	Thrombotic Microangiopathy Associated with Sirolimus Level after Allogeneic Hematopoietic Cell Transplantation with Tacrolimus/Sirolimus-Based Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 298-304.	2.0	100
164	Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). <i>Blood</i> , 2013, 122, 1974-1982.	1.4	92
165	Transplantation For Myelodysplastic Syndrome Evolving From Aplastic Anemia Treated With Immunosuppressive Therapy: From The Fred Hutchinson Cancer Research Center and Center For International Bone Marrow Transplantation Research. <i>Blood</i> , 2013, 122, 924-924.	1.4	0
166	Clinical Evaluation of Safety and Immunogenicity of PADRE-Cytomegalovirus (CMV) and Tetanus-CMV Fusion Peptide Vaccines With or Without PF03512676 Adjuvant. <i>Journal of Infectious Diseases</i> , 2012, 205, 1294-1304.	4.0	86
167	A Phase I Study in Adults of Clofarabine Combined with High-Dose Melphalan as Reduced-Intensity Conditioning for Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 432-440.	2.0	24
168	Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxis. <i>Leukemia Research</i> , 2012, 36, 1152-1156.	0.8	31
169	Tacrolimus/Sirolimus Vs. Tacrolimus/Methotrexate for Graft-Vs.-Host Disease Prophylaxis After HLA-Matched, Related Donor Hematopoietic Stem Cell Transplantation: Results of Blood and Marrow Transplant Clinical Trials Network Trial 0402. <i>Blood</i> , 2012, 120, 739-739.	1.4	19
170	Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation From Unrelated Donors in Severe Aplastic Anemia (SAA): Serious and Unexpected Adverse Events in Pre-Defined Cyclophosphamide (CY) Dose Levels. <i>Blood</i> , 2011, 118, 3009-3009.	1.4	0
171	Detection and Characterization of Antigen-Driven CD8+ T Lymphocytes Specific for Wilms' Tumor Antigen in Patients with Non-Hodgkin Lymphoma. <i>Blood</i> , 2011, 118, 953-953.	1.4	0
172	Response: A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 different conditioning regimens. <i>Blood</i> , 2010, 115, 4317-4317.	1.4	0
173	A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. <i>Blood</i> , 2010, 115, 1098-1105.	1.4	99
174	Improved Outcomes Using Tacrolimus/Sirolimus for Graft-versus-Host Disease Prophylaxis with a Reduced-Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplant as treatment of Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 281-286.	2.0	29
175	Final Report of a Phase I Study of Clofarabine Plus High Dose Melphalan as a Conditioning Regimen for Allogeneic Transplantation. <i>Blood</i> , 2010, 116, 528-528.	1.4	1
176	Improved Outcome After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RI-HCT) for Myelodysplastic Syndrome (MDS) Using Tacrolimus/Sirolimus-Based Gvhd Prophylaxis.. <i>Blood</i> , 2009, 114, 2771-2771.	1.4	2
177	A Retrospective Analysis of Using Pre-Transplant Functional FDG-PET to Predict for Relapse and Survival in Relapsed Hodgkin Lymphoma (HL) Patients Undergoing Autologous Hematopoietic Cell Transplantation (AHCT).. <i>Blood</i> , 2009, 114, 1225-1225.	1.4	0
178	Impact of Graft Cell Dose on Transplant Outcomes following Unrelated Donor Allogeneic Peripheral Blood Stem Cell Transplantation: Higher CD34+ Cell Doses Are Associated with Decreased Relapse Rates. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 449-457.	2.0	63
179	Thrombotic Microangiopathy with Tacrolimus/Sirolimus-Based GVHD Prophylaxis Regimen in Patients Undergoing Hematopoietic Stem Cell Transplant from a Matched Unrelated Donor. <i>Blood</i> , 2008, 112, 797-797.	1.4	1
180	Impact of Donor Serostatus on CMV Reactivation and Reconstitution of Multi-Function CMV-Specific T Cells in CMV-Positive Transplant Recipients. <i>Blood</i> , 2008, 112, 4339-4339.	1.4	0

#	ARTICLE	IF	CITATIONS
181	Chemokine Receptor Gene Polymorphisms and Severity of Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation from Sibling Donors.. Blood, 2007, 110, 4989-4989.	1.4	1
182	Reduced Intensity (RI) Allogeneic Hematopoietic Cell Transplantation (HCT) Improves Outcomes for Older (≥ 60 Yrs) Patients (Pts) with Acute Myeloid Leukemia (AML).. Blood, 2007, 110, 1089-1089.	1.4	0
183	Effect of the Terminal Complement Inhibitor Eculizumab on Patient Reported Outcomes in Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase III Triumph Study Results.. Blood, 2006, 108, 3770-3770.	1.4	4
184	The Use of Sirolimus Combined with Tacrolimus and Low-Dose Methotrexate Is Effective in Preventing Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation.. Blood, 2006, 108, 2866-2866.	1.4	2
185	Cytomegalovirus Infections Following Reduced-Intensity Allogeneic Stem Cell Transplantation.. Blood, 2004, 104, 2245-2245.	1.4	0